Jeffrey L. Quillen

Representative Experience

•  MDxHealth SA (Nasdaq/Euronext: MDXH), a foreign private issuer, in its acquisition of the OncoType DX Genomic Prostate Score business from Exact Sciences Corporation (Nasdaq: EXAS) for cash and equity consideration of up to $100 million, including a multi-year earn-out arrangement.
• Represented RedShift BioAnalytics Inc., a company providing next-generation platform technology enabling measurement of previously undetectable structure changes in biomolecules, in closing its $20 million Series E Preferred Stock financing. 
• Represented H.I.G. BioHealth Partners and Accelmed Partners as new investors and co-leads in the $52 million upsized Series B financing of digital therapeutics company Click Therapeutics, Inc. (“Click”).
• Represented BigVisible Solutions, Inc. in the sale by its shareholders of the business to SolutionsIQ for an undisclosable amount.
• Represented Pervasis Therapeutics in connection with a sale of substantially all of Pervasis’ assets to a subsidiary of Shire plc.
• Represented Zosano Pharma Corporation (Nasdaq: ZSAN) in its initial public offering of 4,500,000 shares of its common stock at a price of $11.00 per share.
• Represented Rinovum Women’s Health, a privately-held, U.S.-based women’s health company, in its Series C funding.
• Represented Selecta Biosciences, Inc., a biopharmaceutical company founded by Dr. Omid Farokhzad and Professors Robert Langer and Ulrich von Andrian, in various equity financings totaling over $50 million, including most recently a $10 million extension of Series D financing.
• Represented NeoGraft Technologies, a development-stage medical device company focused on coronary artery disease, in its $11 million Series C financing.
• Advised scPharmaceuticals, Inc., a biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, in its $16 million Series A venture financing.
• Represented ArthroMeda, Inc., a developer of medical devices designed to improve surgical outcomes for patients undergoing joint replacement procedures, in its Series B financing.
• Advised Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of drugs to treat cancer and other diseases, on numerous financings, including a $16 million Series B financing.

Licensing & Strategic Alliances

• Advised Zosano Pharma Corporation (Nasdaq: ZSAN), a California-based, biotechnology company that is a pioneer in the transdermal drug delivery field, in the negotiation of an agreement with Novo Nordisk A/S to develop a new transdermal presentation of semaglutide.
• Advised Zosano Pharma Corporation (Nasdaq: ZSAN) in its exclusive licensing agreement with Eli Lilly and Company to develop ZP-PTH -- Zosano’s proprietary formulation of parathyroid hormone 1-34 (PTH) -- using Zosano’s microneedle patch system for the treatment of osteoporosis patients.
• Represented Translational Therapeutics Inc. as it entered into a strategic licensing agreement with Clavis Pharma ASA of Norway regarding the development and commercialization of a thyroid cancer treatment.